Literature DB >> 11390611

Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response.

S J Polyak1, K S Khabar, D M Paschal, H J Ezelle, G Duverlie, G N Barber, D E Levy, N Mukaida, D R Gretch.   

Abstract

Hepatitis C virus (HCV), a major cause of liver disease worldwide, is frequently resistant to the antiviral alpha interferon (IFN). The HCV nonstructural 5A (NS5A) protein has been implicated in HCV antiviral resistance in many studies. NS5A antagonizes the IFN antiviral response in vitro, and one mechanism is via inhibition of a key IFN-induced enzyme, the double-stranded-RNA-activated protein kinase (PKR). In the present study we determined if NS5A uses other strategies to subvert the IFN system. Expression of full-length NS5A proteins from patients who exhibited a complete response (FL-NS5A-CR) or were nonresponsive (FL-NS5A-NR) to IFN therapy in HeLa cells had no effect on IFN induction of IFN-stimulated gene factor 3 (ISGF-3). Expression of mutant NS5A proteins lacking 110 (NS5A-DeltaN110), 222 (NS5A-DeltaN222), and 334 amino-terminal amino acids and mutants lacking 117 and 230 carboxy-terminal amino acids also had no effect on ISGF-3 induction by IFN. Expression of FL-NS5A-CR and FL-NS5A-NR did not affect IFN-induced STAT-1 tyrosine phosphorylation or upregulation of PKR and major histocompatibility complex class I antigens. However, NS5A expression in human cells induced interleukin 8 (IL-8) mRNA and protein, and this effect correlated with inhibition of the antiviral effects of IFN in an in vitro bioassay. NS5A induced transcription of a reporter gene driven by the IL-8 promoter, and the first 133 bp of the IL-8 promoter made up the minimal domain required for NS5A transactivation. NS5A-DeltaN110 and NS5A-DeltaN222 stimulated the IL-8 promoter to higher levels than did the full-length NS5A protein, and this correlated with increased nuclear localization of the proteins. Additional mutagenesis of the IL-8 promoter suggested that NF-kappaB and AP-1 were important in NS5A-DeltaN222 transactivation in the presence of tumor necrosis factor alpha and that NF-IL-6 was inhibitory to this process. This study suggests that NS5A inhibits the antiviral actions of IFN by at least two mechanisms and provides the first evidence for a biological effect of the transcriptional activity of the NS5A protein. During HCV infection, viral proteins may induce chemokines that contribute to HCV antiviral resistance and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390611      PMCID: PMC114325          DOI: 10.1128/JVI.75.13.6095-6106.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.

Authors:  D R Taylor; S T Shi; P R Romano; G N Barber; M M Lai
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

2.  Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription.

Authors:  R Lin; C Heylbroeck; P Genin; P M Pitha; J Hiscott
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon.

Authors:  J Song; M Fujii; F Wang; M Itoh; H Hotta
Journal:  J Gen Virol       Date:  1999-04       Impact factor: 3.891

4.  Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.

Authors:  L Frangeul; P Cresta; M Perrin; F Lunel; P Opolon; H Agut; J M Huraux
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

5.  NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling.

Authors:  S L Tan; H Nakao; Y He; S Vijaysri; P Neddermann; B L Jacobs; B J Mayer; M G Katze
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  A suggested extension of the HCV ISDR does not alter our former conclusions on its predictive value for IFN response.

Authors:  K Rispeter; M Lu; A Zibert; M Wiese; J Mendes de Oliveira; M Roggendorf
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

7.  Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection.

Authors:  G Squadrito; M E Orlando; I Cacciola; M G Rumi; M Artini; A Picciotto; O Loiacono; R Siciliano; M Levrero; G Raimondo
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

8.  Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.

Authors:  M Gale; B Kwieciszewski; M Dossett; H Nakao; M G Katze
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus.

Authors:  R T Chung; A Monto; J L Dienstag; L M Kaplan
Journal:  J Med Virol       Date:  1999-08       Impact factor: 2.327

10.  Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication.

Authors:  S J Polyak; D M Paschal; S McArdle; M J Gale; D Moradpour; D R Gretch
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

View more
  83 in total

1.  Hematopoietic growth factors for acute myelogenous leukemia.

Authors:  Matt Kalaycio
Journal:  Curr Hematol Rep       Date:  2004-01

2.  Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC.

Authors:  Sung-Jae Park; Young S Hahn
Journal:  Rev Infect       Date:  2010-07-01

3.  Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Authors:  M Diago; G Castellano; J García-Samaniego; C Pérez; I Fernández; M Romero; O L Iacono; C García-Monzón
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

Review 4.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

6.  Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion.

Authors:  Carey L Medin; Katherine A Fitzgerald; Alan L Rothman
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Viral factors associated with cytokine expression during HCV/HIV co-infection.

Authors:  Jason T Blackard; Minhee Kang; J Benjamin St Clair; Wenyu Lin; Yoshitaka Kamegaya; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Janet Andersen; Raymond T Chung
Journal:  J Interferon Cytokine Res       Date:  2007-04       Impact factor: 2.607

Review 8.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

Review 9.  HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?

Authors:  J T Blackard; K E Sherman
Journal:  J Viral Hepat       Date:  2008-01-17       Impact factor: 3.728

Review 10.  Interaction of hepatitis C virus with the type I interferon system.

Authors:  Friedemann Weber
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.